Pages that link to "Q43911547"
Jump to navigation
Jump to search
The following pages link to Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes (Q43911547):
Displaying 50 items.
- Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review (Q24561401) (← links)
- Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats (Q24793556) (← links)
- Current concepts of cardiovascular diseases in diabetes mellitus (Q28196278) (← links)
- Cardiovascular consequences of cortisol excess (Q28289545) (← links)
- Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome (Q29619211) (← links)
- Insulin resistance in chronic kidney disease: a systematic review (Q30244271) (← links)
- Inflammation in nonalcoholic steatohepatitis (Q30453231) (← links)
- Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes (Q33603551) (← links)
- Relationships between Composition of Major Fatty Acids and Fat Distribution and Insulin Resistance in Japanese. (Q33679044) (← links)
- High-Throughput Screening for Small-Molecule Adiponectin Secretion Modulators (Q33865627) (← links)
- Circulating adiponectin levels are lower in Latino versus non-Latino white patients at risk for cardiovascular disease, independent of adiposity measures (Q33953920) (← links)
- Adiponectin: systemic contributor to insulin sensitivity (Q33966206) (← links)
- Adipose gene expression profiles related to metabolic syndrome using microarray analyses in two different models (Q34404024) (← links)
- Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease (Q34449857) (← links)
- Decreased Plasma Adiponectin Levels in Young Obese Males (Q34542624) (← links)
- Vascular effects of TZDs: new implications (Q34567958) (← links)
- Adiponectin in health and disease (Q34613068) (← links)
- Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome. (Q34856889) (← links)
- Thiazolidinediones could improve endothelial dysfunction and risk of premature coronary heart disease in HIV-infected patients (Q35030013) (← links)
- Lessons in obesity from transgenic animals (Q35037252) (← links)
- The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes (Q35085591) (← links)
- Do peroxisome proliferation receptor-gamma antagonists have clinical potential as combined antiobesity and antidiabetic drugs? (Q35094709) (← links)
- Effects of a moderate low-carbohydrate diet on preferential abdominal fat loss and cardiovascular risk factors in patients with type 2 diabetes (Q35110514) (← links)
- Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans (Q35304374) (← links)
- Adiponectin/Acrp30, an adipocyte-specific secretory factor: physiological relevance during development (Q35600208) (← links)
- Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy (Q35673446) (← links)
- A novel pathway to the manifestations of metabolic syndrome (Q35674454) (← links)
- 1. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands and their therapeutic utility (Q35683565) (← links)
- Adiponectin: linking the metabolic syndrome to its cardiovascular consequences. (Q36124903) (← links)
- Dyslipidaemia in type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone (Q36165296) (← links)
- Insulin resistance: causes and consequences (Q36248033) (← links)
- Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. (Q36283822) (← links)
- Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus (Q36390892) (← links)
- The effects of thiazolidinediones on blood pressure levels - a systematic review (Q36545395) (← links)
- Pleiotropic effects of thiazolidinediones (Q37142044) (← links)
- Adiponectin and its association with insulin resistance and type 2 diabetes (Q37197323) (← links)
- Metabolic impact of adipose and hepatic glycerol channels aquaporin 7 and aquaporin 9. (Q37293154) (← links)
- Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy (Q37311122) (← links)
- Insulin Resistance and Other Metabolic Risk Factors in the Pathogenesis of Hepatocellular Carcinoma (Q37417134) (← links)
- The clinical implications of blood adiponectin in cardiometabolic disorders. (Q37482881) (← links)
- Effects of replacing metformin with pioglitazone on glycemic control in japanese patients with poorly controlled type 2 diabetes mellitus: A 12-week, open-label, prospective study (Q37672754) (← links)
- An observational study of the effect of two thiazolidinediones on blood lipid levels: Rosiglitazone and pioglitazone in routine clinical practice (Q37719114) (← links)
- Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents. (Q37724195) (← links)
- Serum high-molecular-weight adiponectin as a marker for the evaluation and care of subjects with metabolic syndrome and related disorders (Q37800324) (← links)
- A Personalized Approach to Metabolic Aspects of Obesity (Q37801629) (← links)
- Factors determining the risk of the metabolic syndrome: is there a central role for adiponectin? (Q38077655) (← links)
- Effects of PPARgamma ligands and C/EBPbeta enhancer on expression of extracellular-superoxide dismutase (Q38335505) (← links)
- PPARγ signaling and emerging opportunities for improved therapeutics (Q38856983) (← links)
- Cardio-oncology: the Nuclear Option (Q39185620) (← links)
- Medication use for the treatment of diabetes in obese individuals. (Q39304674) (← links)